CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Delabeling for Penicillin Allergy Found Safe in Children

Published: Fri, 20 Apr 2018 08:02:52 EDT
Children with low-risk penicillin allergy symptoms who tested negative for penicillin allergy tolerated penicillin without serious adverse or allergic reactions during the following year, a study found.
Medscape Medical News

CMS Should Have Required a Randomized Trial of F1CDx

Published: Fri, 20 Apr 2018 12:00:00 EDT
Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.
Annals of Oncology
Displaying results 19-20 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor

Published: Mon, 16 Apr 2018 13:47:56 +0000
Just over a year ago, Cyclacel was hit by a late-stage failure in leukemia that sent its shares into a tailspin and pushed an early-stage CDK inhibitor into the spotlight as its most promising candidate. Now, that CDK drug has shown it can stabilize disease in advanced cancers and is ready to be twinned with AbbVie's leukemia drug Venclexta in phase 2.

Antifungal ‘prodrug’ shows promise in bladder cancer: AACR

Published: Mon, 16 Apr 2018 13:11:10 +0000
When bladder cancer progresses to stage 2, invading the muscle, survival drops to 63% at best. A compound that transforms into the antifungal drug ciclopirox as the body metabolizes it inhibits the progression of bladder cancer in mouse models of the disease.

Apitope preps Graves’ disease drug for phase 2 after positive trial

Published: Mon, 16 Apr 2018 11:52:01 +0000
Apitope has taken a step closer to developing the first new treatment option for thyroid disorder Graves’ disease in decades after posting positive results in a first-in-human trial of its ATX-GD-59 antibody.
Displaying results 22-24 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top